Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 induction trial of oral ozanimod (RPC1063) in ulcerative colitis
2015-000319-41Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ozanimod in autoimmune colitis (3 arms), sponsored by Celgene Corporation. Started Jun 2015; status: completed.
02
Drugs
ozanimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2015-000319-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000319-41.